These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

43 related articles for article (PubMed ID: 522553)

  • 1. [Alphamethyldopa and levodopa interaction].
    Sjönell G
    Lakartidningen; 1979 Nov; 76(45):4008. PubMed ID: 522553
    [No Abstract]   [Full Text] [Related]  

  • 2. [Interaction of L-DOPA and pyridoxine (a review of the literature)].
    Uspenskiĭ AE
    Farmakol Toksikol; 1977; 40(6):722-33. PubMed ID: 340258
    [No Abstract]   [Full Text] [Related]  

  • 3. Adverse interaction of levodopa with tricyclic antidepressants.
    Edwards M
    Practitioner; 1982 Aug; 226(1370):1447-9. PubMed ID: 7134159
    [No Abstract]   [Full Text] [Related]  

  • 4. Synergism of levodopa by alpha methyldopa.
    Fermaglich J; O'Doherty DS
    Trans Am Neurol Assoc; 1971; 96():231-4. PubMed ID: 5159089
    [No Abstract]   [Full Text] [Related]  

  • 5. Black cartilage after therapy with levodopa and methyldopa.
    Rausing A; Rosén U
    Arch Pathol Lab Med; 1994 May; 118(5):531-5. PubMed ID: 8192560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Experiences in the treatment of Parkinsonism using a combination of L-dopa and alpha-methyldopa-hydrazine].
    Vymazal J; Roth B; Nevsímal O
    Cesk Neurol Neurochir; 1976 Mar; 39(2):59-62. PubMed ID: 1260921
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of alphamethyldopa on the half-lives of antipyrine, tolbutamide and D-glucaric acid excretion in man.
    Gachályi B; Tornyossy M; Vas A; Káldor A
    Int J Clin Pharmacol Ther Toxicol; 1980 Mar; 18(3):133-5. PubMed ID: 6103880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical evaluation of selegiline (L-deprenyl) in the long-term L-dopa treatment syndrome.
    Trebini F; Daniele D; Gillio S; Scarzella L
    Acta Neurol (Napoli); 1985 Oct; 7(5):432-9. PubMed ID: 3933283
    [No Abstract]   [Full Text] [Related]  

  • 9. 3-O-Methyldopa in Parkinson's disease.
    Muenter MD; Sharpless NS; Tyce GM
    Adv Neurol; 1974; 5():309-15. PubMed ID: 4440579
    [No Abstract]   [Full Text] [Related]  

  • 10. Levodopa-inhibiting effect of pallidal surgery.
    Krack P; Pollak P; Limousin P; Benabid AL
    Ann Neurol; 1997 Jul; 42(1):129-30. PubMed ID: 9225697
    [No Abstract]   [Full Text] [Related]  

  • 11. Temporal relationships between plasma and cerebrospinal fluid pharmacokinetics of levodopa and clinical effect in Parkinson's disease.
    Olanow CW; Gauger LL; Cedarbaum JM
    Ann Neurol; 1991 May; 29(5):556-9. PubMed ID: 1859185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of caffeine on levodopa pharmacokinetics and pharmacodynamics in Parkinson disease.
    Deleu D; Jacob P; Chand P; Sarre S; Colwell A
    Neurology; 2006 Sep; 67(5):897-9. PubMed ID: 16966563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alpha-methyldopa as an adjunct to levodopa treatment of Parkinson's disease.
    Sweet RD; Lee JE; McDowell F
    Trans Am Neurol Assoc; 1971; 96():59-65. PubMed ID: 5159130
    [No Abstract]   [Full Text] [Related]  

  • 14. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
    Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
    Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 3-O-methyldopa and the response to levodopa in Parkinson's disease.
    Nutt JG; Woodward WR; Gancher ST; Merrick D
    Ann Neurol; 1987 Jun; 21(6):584-8. PubMed ID: 3606046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of alphamethyldopa and of phenobarbitone on angiotensin responsiveness and renin activity in man.
    Káldor A; Gachályi B; Kállay K; Fekete S; Földvári A
    Int J Clin Pharmacol Biopharm; 1975 Jan; 11(1):10-4. PubMed ID: 1150359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Reversal of the cardiovascular effects of clonidine by alphamethyldopa].
    Palop R; Rubio E; Morales-Olivas FJ
    Rev Esp Cardiol; 1986; 39(6):446-51. PubMed ID: 3823560
    [No Abstract]   [Full Text] [Related]  

  • 18. Drugs that reduce efficacy of levodopa.
    Hausner R
    N Engl J Med; 1976 Dec; 295(27):1538. PubMed ID: 995166
    [No Abstract]   [Full Text] [Related]  

  • 19. Catechol-O-methyltransferase and Parkinson's disease.
    Reches A; Fahn S
    Adv Neurol; 1984; 40():171-9. PubMed ID: 6695593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Diurnal worsening in Parkinson patients treated with levodopa].
    Piccini P; Del Dotto P; Pardini C; D'Antonio P; Rossi G; Bonuccelli U
    Riv Neurol; 1991; 61(6):219-24. PubMed ID: 1813974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.